Trials / Completed
CompletedNCT02961764
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 313 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Usual Care | Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. |
| DRUG | Dalbavancin | Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes. |
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2019-03-29
- Completion
- 2019-03-29
- First posted
- 2016-11-11
- Last updated
- 2020-04-10
- Results posted
- 2020-04-10
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02961764. Inclusion in this directory is not an endorsement.